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Background: Although the positive association between achieved low-density lipoprotein cholesterol
(LDL-C) level and the risk of coronary artery disease (CAD) has been conﬁrmed by randomized studies
with statins, many patients remain at high residual risk of events suggesting the necessity of novel
pharmacologic strategies. The combination of ezetimibe/statin produces greater reductions in LDL-C
compared to statin monotherapy.
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K. Tsujita et al. / Journal of Cardiology 66 (2015) 353–358354Purpose: The Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated
by IntraVascular UltraSound (PRECISE-IVUS) trial was aimed at evaluating the effects of ezetimibe
addition to atorvastatin, compared with atorvastatin monotherapy, on coronary plaque regression and
change in lipid proﬁle in patients with CAD.
Methods: The study is a prospective, randomized, controlled, multicenter study. The eligible patients
undergoing IVUS-guided percutaneous coronary intervention will be randomly assigned to receive
either atorvastatin alone or atorvastatin plus ezetimibe (10 mg) daily using a web-based randomization
software. The dosage of atorvastatin will be increased by titration within the usual dose range with a
treatment goal of lowering LDL-C below 70 mg/dL based on consecutive measures of LDL-C at follow-up
visits. IVUS will be performed at baseline and 9–12 months follow-up time point at participating
cardiovascular centers. The primary endpoint will be the nominal change in percent coronary atheroma
volume measured by volumetric IVUS analysis.
Conclusion: PRECISE-IVUS will assess whether the efﬁcacy of combination of ezetimibe/atorvastatin is
noninferior to atorvastatin monotherapy for coronary plaque reduction, and will translate into increased
clinical beneﬁt of dual lipid-lowering strategy in a Japanese population.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
HMG-CoA reductase inhibitors
Plaque
Intravascular ultrasoundTable 1
Inclusion criteria.
1. Patients who agree to be enrolled in the trial giving signed written informed
consent
2. Aged 30–85 years at the time of their consent
3. Patients who have been diagnosed as ACS or stable coronary heart disease
4. Patients who undergo CAG or PCI under IVUS guidance
5. Patients with LDL-C 100 mg/dL at the time of their consent
ACS, acute coronary syndrome; CAG, coronary angiography; PCI, percutaneous
coronary intervention; IVUS, intravascular ultrasound; LDL-C, low-density
lipoprotein cholesterol.Introduction
Cardiovascular (CV) disease remains the leading cause of death
and a major cause of disability affecting quality of life [1]. Increased
levels of blood cholesterol are causally related to an increased
risk of coronary heart disease (CHD). Consistent with global
studies, the age- and gender-adjusted incidences of CHD have been
shown to signiﬁcantly increase with increasing low-density
lipoprotein cholesterol (LDL-C) levels [2]. Also, the positive
association between achieved LDL-C level and the risk of CHD
has been conﬁrmed by randomized trials of lipid lowering [3]. In
recognition of the beneﬁts of intensive lipid-lowering therapy, the
US National Cholesterol Education Program published an update
document, suggesting a lower optional therapeutic goal for LDL-C
in high-risk patients [4].
However, despite current standards of care aimed at achieving
targets for LDL-C with the use of 3-hydroxy-3-methyl-glutaryl
coenzyme A (HMG-CoA) reductase inhibitors (statins), many
patients continue to experience CV events and remain exposed
to a high ‘‘residual risk’’ of future acute coronary events. Therefore,
additional novel pharmacologic strategies for the prevention of
CHD remain essential, particularly for high-risk patients [e.g.
diabetic, or with acute coronary syndrome (ACS)].
On the other hand, ezetimibe inhibits the absorption of biliary
and dietary cholesterol from the small intestine by blocking the
Niemann-Pick C1 Like 1 receptor. Its addition to statin therapy
leads to further decreases in LDL-C levels by 12–14%, allowing a
greater proportion of patients to reach their National Cholesterol
Education Program goal [5–7]. IMPROVE-IT will determine
whether the addition of ezetimibe to statin therapy, using
ezetimibe/simvastatin, improves CV outcomes compared with
simvastatin monotherapy in patients after ACS [8]. However,
whether the additional LDL-C lowering achieved with the addition
of ezetimibe to statin therapy will lead to stronger coronary plaque
regression is currently unknown [9]. Also, whether the difference
of lipid-lowering strategy (sole inhibition of cholesterol synthesis
vs. combined inhibition of synthesis and absorption) would have
an impact on the plaque progression/regression has been not well
understood. Thus, the Plaque REgression with Cholesterol absorp-
tion Inhibitor or Synthesis inhibitor Evaluated by IntraVascular
UltraSound (PRECISE-IVUS) trial was designed to evaluate the
effects of ezetimibe (cholesterol absorption inhibitor) addition to
atorvastatin (cholesterol synthesis inhibitor), compared with
atorvastatin monotherapy, on coronary plaque regression and
change in lipid proﬁle in patients with CHD. The study will also
assess whether the efﬁcacy of combination of ezetimibe/atorvas-
tatin is noninferior to atorvastatin monotherapy for plaque
reduction.Study design
Study protocol
PRECISE-IVUS will be a prospective, randomized, controlled,
assessor-blind, multicenter study to evaluate the effect of
ezetimibe addition to atorvastatin on coronary artery atheroma
volume as measured by IVUS in patients with CHD. Patients who
satisfy all criteria for inclusion will be enrolled after having
undergone successful coronary angiography (CAG) or percutane-
ous coronary intervention (PCI) under IVUS guidance to treat an
episode of ACS or stable CHD (Table 1). Exclusion criteria are listed
in Table 2. According to the criteria, the eligible patients will give
written informed consent and then be randomly assigned to
receive either atorvastatin alone or atorvastatin plus ezetimibe
(10 mg) daily using a web-based randomization software con-
ducted at the Large-Scale Clinical Trial Promotion Unit of the
Department of Cardiovascular Medicine, Graduate School of
Medical Sciences, Kumamoto University (Fig. 1). Minimization, a
dynamic randomization method that can balance groups with
respect to both the numbers in each treatment arm and the
characteristics of each group, will be utilized in the PRECISE-IVUS
trial [10]. The randomization will be stratiﬁed by 1) gender, 2) age,
3) history of hypertension, 4) history of diabetes, 5) history of
peripheral arterial disease, 6) serum LDL-C level, 7) serum high-
density lipoprotein cholesterol (HDL-C) level, 8) serum triglyceride
(TG) level, and 9) statin pretreatment prior to study enrollment.
The dosage of atorvastatin will be increased by titration within the
usual dose range with a treatment goal of lowering LDL-C below
70 mg/dL based on Western lipoprotein management guidelines
[11]. If LDL-C levels are still 70 mg/dL or above, the atorvastatin
dosage may be increased up to a maximum dose. If the investigator
ﬁnds it necessary to reduce the dosage because of an excessive
decrease in LDL-C or occurrence of adverse events, the dosage may
be reduced again to a minimum dose at the discretion of the
participating physician. The participants will continue taking the
Table 2
Exclusion criteria.
1. Patients with familial hypercholesterolemia
2. Patients treated with ezetimibe
3. Patients treated with ﬁbrates
4. Renal insufﬁciency (serum creatinine 2.0 mg/dL)
5. Altered hepatic function (serum AST or ALT  3-folds of standard value in each
institute)
6. Patients undergoing hemodialysis or peritoneal dialysis
7. Any allergy to atorvastatin or ezetimibe
8. Severe underlying disease
9. Lack of decision-making capacity
10. Patients recognized as inadequate by attending physician
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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the participants for 9–12 months at participating centers or
general physician’s clinics, and will conduct medical examinations
and blood testing. IVUS and CAG will be performed at baseline and
9–12 months follow-up time point at participating cardiovascular
centers. This study is approved by the Institutional Review Board
or Independent Ethics Committee of all of the participating centers.
The planned duration is between October 2010 and September
2014 and the enrollment period may be extended if necessary. This
study has been registered at clinicaltrials.gov (NCT01043380),
according to the statement of the International Committee of
Medical Journal Editors.
IVUS acquisition and analysis
The PRECISE-IVUS trial uses IVUS to trace lumen and vessel
border, and to calculate coronary atheroma parameters at baseline
and after trial treatment. Investigators will be required to use the
same IVUS imaging system [40–45 MHz mechanical rotational
commercially available IVUS imaging catheter (Boston Scientiﬁc,
Natick, MA, USA; Terumo Corp., Tokyo, Japan; Volcano Corp.,
Rancho Cordova, CA, USA) and console] for both the baseline and
follow-up IVUS image acquisition. Before imaging, intracoronary
nitroglycerin 0.1 to 0.2 mg was administered. The IVUS catheter
was advanced into the PCI or non-PCI vessel as distally as possible
and withdrawn at a pullback speed of 0.5 mm/s automatically.
IVUS images will be recorded onto CD-R for later ofﬂine analysis.
The images will be logged and qualitative IVUS analysis will be
performed by 2 independent blinded experienced observers in theFig. 1. Flow chart of the study timeline. Patients will be allocated to either
atorvastatin monotherapy or atorvastatin/ezetimibe combination therapy. The
target low-density lipoprotein cholesterol (LDL-C) level will be <70 mg/dL, in
which atorvastatin is titrated by increasing the dosage up to a maximum dose daily.
At the baseline and 9–12 month follow-up period, coronary angioscopy and
intravascular ultrasound are performed. ACS, acute coronary syndrome; SAP, stable
angina pectoris; CAG, coronary angiography; PCI, percutaneous coronary
intervention; IVUS, intravascular ultrasound.IVUS core lab at the Department of Cardiovascular Medicine,
Graduate School of Medical Sciences, Kumamoto University
according to the Clinical Expert Consensus Document on Standards
for Acquisition, Measurement and Reporting of Intravascular
Ultrasound Regression/Progression Studies [12]. IVUS exclusion
criteria might include 1) calciﬁed plaque, 2) any cross-sections
with a recognizable non-uniform rotation distortion (NURD), 3)
presence of external elastic membrane out of view, 4) loss of image
due to bubbles, or 5) any other artifact that prevents complete
analysis. Coronary atheroma parameters will be assessed by
volumetric analysis with the echoPlaque3 system (INDEC Systems,
Inc., Mountain View, CA, USA). Baseline and follow-up IVUS images
will be reviewed side-by-side on a display, and the target segment
will be selected. The target segment to be monitored will be
determined in a non-PCI site (>5 mm proximal or distal to the PCI
site) on the PCI or non-PCI vessel with a reproducible ﬁduciary
index such as side branches, calciﬁcations, or stent edges.
Endpoints
Based on an expert consensus document paper [12], the
primary endpoint will be the absolute change in percent coronary
atheroma volume from baseline to follow-up. The secondary
endpoints will include 1) percent change in atheroma volume, 2)
absolute and percent changes in lipid, glycemic, and inﬂammatory
proﬁle [total cholesterol, LDL-C, TG, HDL-C, HDL2-C, HDL3-C,
remnant-like lipoprotein particles cholesterol (RLP-C), small dense
LDL, oxidized LDL, free-fatty acid, apoA-I, apoB, apoC-II, apoC-III,
lipoprotein (a), fasting insulin level, hemoglobin A1c, adiponectin,
lathosterol, cholestanol, sitosterol, campesterol, high sensitive C-
reactive protein (hsCRP)], 3) correlation between regression of
coronary plaque and the lipid, glycemic, and inﬂammatory
markers, 4) major adverse cardiovascular events [MACE; deﬁned
as cardiac death, Q or non-Q wave myocardial infarction, target
vessel revascularization (PCI or coronary artery bypass grafting)],
5) all-cause death, and 6) any adverse incidents including changes
in laboratory values. The above-mentioned laboratory measure-
ments will be performed at a central clinical laboratory (SRL, Inc,
Tokyo, Japan). LDL-C was measured using a direct LDL-C
homogeneous assay.
Safety monitoring
Safety will be observed throughout the study, and be evaluated
by regular medical examination and laboratory tests at 3, 6, and 9–
12 months after enrollment. The Data and Safety Monitoring
Committee (DSMC) will evaluate MACE and any other adverse
events.
Sample size calculation
The effect of combination of atorvastatin/ezetimibe on coronary
atheroma volume reduction, compared with atorvastatin mono-
therapy, has not been determined. The sample size calculation was
thus performed based on the assumption that the effect of
atorvastatin/ezetimibe combination therapy on the regression of
coronary atheroma volume is not inferior to that of atorvastatin
monotherapy, referencing the similar prior study accomplished in
Japan, JAPAN-ACS study [13]. The nominal change in percent
coronary atheroma volume in patients participating in the JAPAN-
ACS study was 6.3  6.1% in an atorvastatin monotherapy group.
We assumed that the mean and standard deviation of the nominal
change in percent coronary atheroma volume in patients receiving
atorvastatin/ezetimibe combination therapy were equal to those with
atorvastatin monotherapy reported in the study. Based on the
standard deviation in the atorvastatin monotherapy group, we
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jects in each group with an alpha level of 5%, a power of 80%. A key
secondary objective was to determine whether atorvastatin/ezeti-
mibe combination was superiority to atorvastatin monotherapy with
respect to the nominal change in percent coronary atheroma volume.
Discussion
Attainment rate of target LDL-C levels and safety
The European guidelines for the management of dyslipidemia
recommend aggressive lipid-lowering therapy targeting LDL-C
<70 mg/dL in patients with CAD [14]. On the contrary, according to
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of
Atherosclerotic Cardiovascular Diseases 2012 [15], the target LDL-
C level for secondary prevention of atherosclerosis is currently
<100 mg/dL. Despite the looser setting of target level of LDL-C, the
attainment rate of these target LDL-C levels in patients treated
with statins was less than 25% [16]. However, several studies
demonstrated that statin/ezetimibe combination therapy (espe-
cially with strong statins) could help attain the guideline-
recommended strict LDL-C goals [17]. Given these ﬁndings, the
treatment strategies [atorvastatin/ezetimibe or atorvastatin
monotherapy (dose titration)] planned in the PRECISE-IVUS trial
will be expected to attain the LDL-C target levels of <70 mg/dL.
Difference in likelihood of plaque regression between ACS and stable
angina
A signiﬁcant regression in the coronary atheroma volume has
been reported in previous studies using statins and other agents.
Previous studies have suggested that statin-induced regression in
coronary atherosclerosis appeared to be more prominent in
patients with ACS [13.1% to 18.1% in median percentage of
change in total atheroma volume (TAV)] [13,18] than in patients
with stable coronary artery disease (0.4% to 6.8% in median
percentage of change in TAV) [19,20]. Therefore, an association
between the coronary plaque regression induced by statin therapy
and patients’ clinical presentation, such as stable coronary artery
disease or unstable status, has been speculated. However, little has
been studied regarding this association in a randomized study
design prospectively. The PRECISE-IVUS trial will clarify this in a
current clinical setting.
Clinical implication of the PRECISE-IVUS trial
Although a variety of factors could potentially inﬂuence the
treatment effect of ezetimibe in the PRECISE-IVUS trial, a positive
result will support the concept that combination of ezetimibe/
statin could be an effective treatment especially for high-risk
patients (e.g. individuals with high baseline LDL-C values, patients
with diabetes, patients with established cardiovascular disease,
and individuals with familial hypercholesterolemia). A positive
result will also provide evidence supporting the concept that
ezetimibe can be effective in patients who are unable to tolerate
high-dose statins, those who may better tolerate a combination of
low-dose statin plus ezetimibe, and those who do not achieve
adequate LDL-C lowering despite high-dose statin use.
Given the combination effect of statin/ezetimibe previously
demonstrated in the existing studies, whereas combined therapy
with ezetimibe/simvastatin failed to show a signiﬁcant difference in
changes in intima-media thickness, as compared with simvastatin
alone, in the Ezetimibe and Simvastatin in Hypercholesterolemia
Enhances Atherosclerosis Regression (ENHANCE) trial [21], the
SHARP (Study of Heart and Renal Protection) trial provided evidence
for safe and effective lowering of LDL-C with a combination ofezetimibe/simvastatin among a wide range of patients with chronic
kidney disease [22]. Furthermore, in the SEAS (Simvastatin and
Ezetimibe in Aortic Stenosis) trial conducted among patients with
aortic stenosis, although there were no differences in preventive
effect on major cardiovascular diseases, combination therapy was
signiﬁcantly superior to placebo in terms of preventive effect on
ischemic heart disease [23]. Our IVUS ﬁndings from the PRECISE-
IVUS trial would thus provide additional ﬁndings regarding possible
underlying mechanisms of the above-mentioned beneﬁcial effects
of combination therapy on CV outcomes.
New cholesterol treatment guideline released by the American College
of Cardiology/American Heart Association
The American College of Cardiology/American Heart Association
(ACC/AHA) Task Force on Practice Guidelines has recently released
the new cholesterol treatment guideline [24]. The new cholesterol
treatment guideline emphasizes matching the intensity of statin
treatment to the level of atherosclerotic cardiovascular disease
(ASCVD) risk (‘‘ﬁre and forget’’ concept) and replaces the old
paradigm of pursuing low-density lipoprotein cholesterol targets
(‘‘treat to target’’ concept). First of all, extrapolating the ACC/AHA
recommendation into the current Japanese clinical setting, high-
intensity therapy (50% LDL-C reduction), namely atorvastatin of
40–80 mg daily or rosuvastatin of 20–40 mg daily, has not been
approved in the Japanese healthcare services provided by health
insurance. Furthermore, the new guideline does not recommend
treatment to reach a particular LDL-C, because the panel did not
ﬁnd any evidence of treating to a target. On the other hand,
however, Boekholdt et al. showed that patients who achieve very
low LDL-C levels have a lower risk for major cardiovascular events
than do those achieving moderately low levels, supporting the
concept of ‘‘the lower, the better’’ [25]. In addition, Nicholls et al.
demonstrated that a direct relationship was observed between
the burden of coronary atherosclerosis, its progression, and
adverse cardiovascular events [26]. These data support the use
of atherosclerosis imaging with IVUS in the evaluation of novel
antiatherosclerotic therapies. A positive result of the PRECISE-IVUS
trial could also lead to an early re-evaluation of the new ACC/AHA
lipid management guidelines that endorse statins as the only
recommended drugs for treating cholesterol-related CV risk.
Conclusion
PRECISE-IVUS will assess whether the efﬁcacy of combination
of ezetimibe/atorvastatin is noninferior to atorvastatin mono-
therapy for coronary plaque reduction, and will give us new
insights into real-world information about lipid-lowering and
suppression of coronary atheroma progression in Japan.
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Study organization
Principal investigator:
Hisao Ogawa, Kumamoto University
Steering committee:
Seigo Sugiyama, Jinnouchi Hospital
Hitoshi Sumida, Kumamoto Central Hospital
Kenichi Tsujita, Kumamoto University
Core laboratory:
Kenichi Tsujita, Kumamoto University
Study statistician:
Kunihiko Matsui, Yamaguchi University Hospital
Data and safety monitoring committee:
Kazuo Kimura, Yokohama City University Medical Center
Satoshi Yasuda, National Cerebral and Cardiovascular Center
Participating hospitals and collaborators of PRECISE-IVUS
trial.
1. Fukuoka Tokushukai Medical Center: H Shimomura, Y Yamada, Y
Nakamura, T Kudo, S Morisaki, Y Ogura, T Nagata, N Chazono, K
Yamanaga, Y Onoue, Y Matsumuro
2. Kumamoto University Hospital: H Ogawa, S Hokimoto, K Kaikita,
S Tayama, K Tsujita, K Sakamoto, E Akiyama, N Komura, K
Yamanaga, T Ono
3. Social Insurance Omuta Tenryo Hospital: K Matsuyama, T
Yamashita, M Miura, T Chitose
4. New Tokyo Hospital: S Nakamura, S Mitomo
5. Shin-Beppu Hospital: N Nakamura, K Kikuta, K Watanabe, T
Miyazaki
6. Kumamoto City Hospital: Y Morikami, Y Miyazaki, M Fukuda, H
Nako
7. Japan Labor Health and Welfare Organization Kumamoto Rosai
Hospital: T Matsuura, H Doi, K Abe, N Tabata
8. Health Insurance Hitoyoshi General Hospital: H Oka, S Nakamura
9. Amakusa Medical Center: N Sakaino, S Nakamura, T Nozaki
10. Arao City Hospital: I Kajiwara, Enomoto K, D Sueta
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12. Saiseikai Kumamoto Hospital: K Nakao, T Sakamoto, S Miya-
moto, E Taguchi, T Fukunaga, T Tokitsu, S Ogawa
13. Miyazaki Prefectural Nobeoka Hospital: N Yamamoto, K Kurogi,
R Fukushima
14. Social Insurance Kumamoto General Hospital: S Koide, T Uemura
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Nishijima, K Morihisa
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